Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEISMiC
2020-000885-40Phase 2Completed
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cardiogenic shock and heart failure (HF) comparing Istaroxime with Placebo (2 arms). Started Jun 2020; status: completed.
02
Drugs
istaroxime
03
Conditions
cardiogenic shockheart failure (HF)
Beyond the preview
Go deeper on 2020-000885-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000885-40.